A viral antibody vaccine has been approved for use in Africa and Asia, potentially making it more affordable to people living with HIV.
The vaccine was approved by the U.S. Food and Drug Administration (FDA) on Wednesday.
The announcement came in a news release announcing the approval.
The approval marks the first time that a vaccine has reached the U, Africa and Australia, said Dr. Daniel V. Bovell, chairman of the infectious diseases department at Columbia University’s Mailman School of Public Health.
The approval was made possible by an extensive collaboration between the CDC, the European Union, and the University of California, San Francisco, and was based on scientific evidence.
The vaccines, called rVSV-19 and rVSD-19, were developed in collaboration with the CDC and were approved in October 2016.
The U.K.-based company Biogen and the Chinese company Sanofi Pasteur announced last week that they had received approval for the vaccine, which was developed by the company.
“The rVSVs have an extremely long half-life, and once the virus has passed the immune system, there is little or no chance that the immune response will be able to defeat the virus,” said Boveill.
“We believe that by targeting the immune pathway, the rVSNV-19 vaccine will be more likely to prevent and treat the viral infection.”
The rVSEV vaccine has a longer half-lives than previous vaccines, which has led some scientists to suggest it may be more effective than existing HIV vaccines.
Viruses such as the rV1 and rV2 strains of HIV are resistant to some current HIV drugs, but not others.
The rVEV-9 vaccine was developed to treat the severe allergic reaction to the rAVD-9 gene.
The rVREV-10 vaccine targets the immune-stimulating factor (ISF), which is required for the immune cells to respond to foreign DNA and proteins.
The vaccine is available for purchase through the National Institutes of Health (NIH) Vaccine Development Program.
The news of rVSVS-19’s approval comes amid a push by HIV prevention advocates to push for the development of an AIDS vaccine.
The World Health Organization recently urged countries to consider expanding HIV prevention efforts, while a coalition of U.N. agencies, the World Health Organizing Body, and major U.s. hospitals have pushed for the creation of a universal AIDS vaccine that would be made available to all.
In the past, some vaccine candidates have failed to make it to clinical trials, with some claiming that there was insufficient evidence for the efficacy of the drug.
The FDA announced Wednesday that it had approved the rVEXV-17 and rVEVEVV-18 vaccines for HIV-infected people living in the U., Africa and the U.-Asia Pacific region, which include Australia, Indonesia, Malaysia, New Zealand, Philippines, Singapore, Thailand, and Vietnam.
“These vaccines are critical to the efforts to eradicate the virus, and we are thrilled that they will now be available for people in the regions where we can deliver them safely and affordably,” said FDA Commissioner Margaret Hamburg in a statement.
“The rNVSEV-14 vaccine is also being developed for HIV prevention in Africa.”
The FDA approval came after months of intense public scrutiny and pressure on the FDA.
In August 2016, President Donald Trump signed an executive order calling for the FDA to review whether the rNVS-19-containing vaccine is safe and effective, after the agency said the vaccine would have been effective in the first two years of its development.
“This announcement shows the agency is committed to taking the first steps toward a new, universal HIV vaccine, and our priority is to ensure that this is an accessible vaccine for all who need it,” said Vadim Vrublevsky, CEO of the Center for Infectious Disease Research and Policy, a nonprofit organization focused on HIV prevention.
“It is our hope that the FDA will soon take a comprehensive look at the rVTV-2 vaccine and provide its approval in order to ensure a vaccine that is equally effective for all HIV-positive people.”
For more news on the news, visit the Bloomberg Businessweek website.